Company Filing History:

6 out of 247

Rhone-poulenc Rorer S.a.

patents

Aventis Pharma Limited

Aventis Pharmaceuticals Inc.

patents

6. 1 out of 832,880

Other

patents

Years Active: 1996-2014

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8852878 - Method for identifying an antagonist of guanine nucleotide releasing factor 1 (2014-10-07),

2. 8431119 - Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases (2013-04-30),

3. 7273854 - Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative disorders (2007-09-25),

4. 6660757 - Use of riluzole in the treating acoustic traumas (2003-12-09),

5. 6617316 - Oligosaccharides, their preparation and pharmaceutical compositions containing them (2003-09-09),

6. 6432992 - Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy (2002-08-13),

7. 6380173 - Use of low-molecular-weight heparins for the prevention and treatment of trauma of the central nervous system (2002-04-30),

8. 6297254 - Method for the prevention or treatment of a motoneuron disease (2001-10-02),

9. 5830907 - Application of riluzole in the treatment of neurological lesions (1998-11-03),

10. 5686475 - Application of riluzole in the treatment of mitochondrial diseases (1997-11-11),

11. 5674885 - Application of riluzole in the treatment of parkinson's disease and (1997-10-07),

12. 5658900 - Application of carbamazepine and oxcarbazepine in the treatment of (1997-08-19),

13. 5656647 - Application of riluzole for promoting restoration following radiation (1997-08-12),

14. 5502049 - Use of phenothiazine derivatives in the treatment of ischaemia and/or (1996-03-26),

Title: The Innovative Contributions of Jean-Marie Stutzmann

Introduction

Jean-Marie Stutzmann is a notable inventor based in Villecresnes, France. He has made significant contributions to the field of neuroscience through his innovative patents. With a total of 14 patents to his name, Stutzmann's work focuses on addressing critical issues related to neurodegenerative diseases.

Latest Patents

Stutzmann's latest patents include a method for identifying an antagonist of guanine nucleotide releasing factor 1. This invention involves the use of the GRF1 protein or cells expressing this protein to detect compounds that may prevent or treat central nervous system pathologies, such as cerebral ischemia, Parkinson's disease, and Alzheimer's disease. Another significant patent relates to pharmaceutical compositions that target the p53 protein or its gene, providing methods for treating neurodegenerative diseases.

Career Highlights

Throughout his career, Stutzmann has worked with prominent companies in the pharmaceutical industry, including Rhone-Poulenc Rorer S.A. and Aventis Pharma S.A. His expertise in the field has allowed him to contribute to groundbreaking research and development efforts.

Collaborations

Stutzmann has collaborated with notable colleagues, including Adam Doble and Erik Louvel. These partnerships have further enhanced his research and innovation capabilities.

Conclusion

Jean-Marie Stutzmann's contributions to the field of neuroscience through his patents and collaborations highlight his commitment to advancing medical science. His work continues to pave the way for new treatments for neurodegenerative diseases.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com